Combination of everolimus with trastuzumab plus paclitaxel as first-line treatment for patients with HER2-positive advanced breast cancer (BOLERO-1): a phase 3, randomised, double-blind, multicentre trial-Reference-Cited by-同舟云学术

Combination of everolimus with trastuzumab plus paclitaxel as first-line treatment for patients with HER2-positive advanced breast cancer (BOLERO-1): a phase 3, randomised, double-blind, multicentre trial

Published:2015-07 Issue:7 Volume:16 Page:816-829
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Hurvitz Sara A,Andre Fabrice,Jiang Zefei,Shao Zhimin,Mano Max S,Neciosup Silvia P,Tseng Ling-Min,Zhang Qingyuan,Shen Kunwei,Liu Donggeng,Dreosti Lydia M,Burris Howard A,Toi Masakazu,Buyse Marc E,Cabaribere David,Lindsay Mary-Ann,Rao Shantha,Pacaud Lida Bubuteishvili,Taran Tetiana,Slamon Dennis

Publisher

Elsevier BV

Subject

Oncology

Reference35 articles.

1. Adjuvant trastuzumab in HER2-positive breast cancer;Slamon;N Engl J Med,2011

2. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene;Slamon;Science,1987

3. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer;Slamon;Science,1989

4. Expression of the HER1–4 family of receptor tyrosine kinases in breast cancer;Witton;J Pathol,2003

5. Trastuzumab–mechanism of action and use in clinical practice;Hudis;N Engl J Med,2007

Cited by 264 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. PI3K PROTAC overcomes the lapatinib resistance in PIK3CA-mutant HER2 positive breast cancer;Cancer Letters;2024-08

2. Effect of Rutin on Pulmonary Injury in Everolimus-Administered Rats Biochemical and Histopathological Evaluation;International Journal of Pharmacology;2024-08-01

3. Evolving Management of Breast Cancer in the Era of Predictive Biomarkers and Precision Medicine;Journal of Personalized Medicine;2024-07-03

4. The evolving landscape of metastatic HER2-positive, hormone receptor-positive Breast Cancer;Cancer Treatment Reviews;2024-07

5. Resistance to Targeted Inhibitors of the PI3K/AKT/mTOR Pathway in Advanced Oestrogen-Receptor-Positive Breast Cancer;Cancers;2024-06-18